Show simple item record

dc.contributor.authorHailu, Asrat*
dc.contributor.authorDiro, Ermias*
dc.contributor.authorKolja, Stille*
dc.contributor.authorRitmeijer, Koert*
dc.contributor.authorYifru, Sisay*
dc.contributor.authorGriensven, Johan van*
dc.contributor.authorZijstra, Ed*
dc.contributor.authorDorlo, Thomas*
dc.contributor.authorStrub-Wougaft, Nathalie*
dc.contributor.authorBardonneau, Clelia*
dc.contributor.authorEllis, Sally*
dc.contributor.authorAlexander, Neal*
dc.contributor.authorEdwards, Tansy*
dc.date.accessioned2018-07-31T13:29:18Z
dc.date.available2018-07-31T13:29:18Z
dc.date.issued2018-07
dc.identifier.urihttp://hdl.handle.net/10144/619245
dc.descriptionResearch Protocolen
dc.description.abstractGeneral Objectives The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected patients. Primary Objective: To evaluate at day 29 assessment the efficacy of a combination regimen of AmBisome® + miltefosine and AmBisome® monotherapy in Ethiopian co-infected HIV + VL patients. Secondary Objectives: 1. To evaluate relapse-free survival at day 390 (after initial cure at day 29 or cure at day 58 after extended treatment). 2. To assess safety of the regimens. Other objectives: 1.To evaluate of viral load and CD4 count in all patients 2. To evaluate the pharmacokinetics of ARV, Ambisome and miltefosine and immune function markers in a subset of patients
dc.language.isoenen
dc.rightsThese materials can be used, adapted and copied as long as citation of the source is given including the direct URL to the material. This work is licensed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0/ https://i.creativecommons.org/l/by/4.0/88x31.pngen
dc.subjectAmBisome monotherapyen
dc.subjectmiltefosineen
dc.subjectVL HIV positiveen
dc.subjectThiopiaen
dc.subjectpentamidineen
dc.titleA randomized trial of AmBisome monotherapy and combination of AmBisome and miltefosine for the treatment of VL in HIV positive patients in Ethiopia followed by secondary VL prophylactic treatment with pentamidineen
dc.typeOtheren
dc.contributor.departmentMSF-OCAen
refterms.dateFOA2019-03-04T14:03:59Z
html.description.abstractGeneral Objectives The overall objective of this trial is to identify a safe and effective treatment for VL in HIV coinfected patients. Primary Objective: To evaluate at day 29 assessment the efficacy of a combination regimen of AmBisome® + miltefosine and AmBisome® monotherapy in Ethiopian co-infected HIV + VL patients. Secondary Objectives: 1. To evaluate relapse-free survival at day 390 (after initial cure at day 29 or cure at day 58 after extended treatment). 2. To assess safety of the regimens. Other objectives: 1.To evaluate of viral load and CD4 count in all patients 2. To evaluate the pharmacokinetics of ARV, Ambisome and miltefosine and immune function markers in a subset of patients


Files in this item

Thumbnail
Name:
1a_-_DNDi_Protocol_HIV_VL_FINA ...
Size:
620.8Kb
Format:
PDF
Description:
Research Protocol

This item appears in the following Collection(s)

Show simple item record